New drug cocktail takes on rare, aggressive breast cancer
NCT ID NCT03202316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining an immunotherapy (atezolizumab), a targeted therapy (cobimetinib), and a chemotherapy (eribulin) can shrink tumors in people with inflammatory breast cancer that has returned or spread. About 37 participants will receive either the triple combo or a double combo (atezolizumab plus eribulin). The main goal is to see how many patients respond, while also monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab, cobimetinib, and eribulin
- What this could lead to
- If successful, this could point toward a new combination treatment for inflammatory breast cancer that has spread, potentially improving response rates.
- What could go wrong
- This is a small, early-phase trial (37 people) with no control group, so results may not apply broadly. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT BREAST INFLAMMATORY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States